Welcome to our dedicated page for Revelation Biosciences news (Ticker: REVB), a resource for investors and traders seeking the latest updates and insights on Revelation Biosciences stock.
Revelation Biosciences, Inc. reports developments as a clinical-stage life sciences company focused on rebalancing inflammation with its proprietary formulation Gemini. Company updates center on Gemini programs for acute kidney injury, chronic kidney disease, prevention of post-surgical infection, and severe burn-related hyperinflammation and infection.
Recurring announcements include clinical data from the PRIME study, FDA interactions tied to the AKI development pathway, advisory and conference activity, quarterly financial results, warrant inducement financings, proxy matters, and capital-structure actions such as reverse stock splits and Nasdaq listing compliance matters.
Revelation Biosciences Inc. (NASDAQ: REVB) announced the enrollment of 15 patients in a Phase 2b viral challenge study for the intranasal therapy REVTx-99, targeting H3N2 influenza prevention. This study, conducted in Belgium, aims to evaluate REVTx-99's efficacy against respiratory viral infections by activating an innate immune response. The company expects topline data by Q2 2022.
REVTx-99 may also be applicable for SARS-CoV-2 and other respiratory viruses, addressing a significant need for new therapeutic options amid ongoing viral challenges.
Revelation Biosciences (NASDAQ: REVB) has initiated patient enrollment for a Phase 1b clinical study of REVTx-99, targeting allergic rhinitis and chronic nasal congestion. The randomized, placebo-controlled study aims to assess the safety and tolerability of REVTx-99, with results expected in the first half of 2022. Allergic rhinitis affects approximately 8% of adults and 7% of children in the U.S., increasing asthma risk. REVTx-99 is designed to stimulate the nasal immune system, offering a potential treatment for millions suffering from these conditions.
Revelation Biosciences Inc. (NASDAQ: REVB) reported a significant reduction of over 50% in SARS-CoV-2 Delta viral load after treatment with REVTx-99 in three independent in vitro assays. The company has completed its business combination with Petra Acquisition, Inc., effective January 11, 2022, and is listed under symbols REVB and REVBW. The investigational drug REVTx-99 stimulates protective immune responses and is being developed for multiple viral infections, including COVID-19 and influenza. The firm aims to advance its protective therapy amid the ongoing COVID-19 pandemic.